In the latest session, Krystal Biotech Inc (NASDAQ: KRYS) closed at $170.84 up 6.81% from its previous closing price of $159.95. In other words, the price has increased by $+10.89 from its previous closing price. On the day, 1047526 shares were traded.
Ratios:
For a deeper understanding of Krystal Biotech Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.55 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Buy rating and assigned the stock a target price of $160.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $100.
On October 12, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $160.Citigroup initiated its Buy rating on October 12, 2023, with a $160 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 28 when ROMANO KATHRYN sold 7,500 shares for $166.05 per share. The transaction valued at 1,245,381 led to the insider holds 12,936 shares of the business.
ROMANO KATHRYN sold 5,000 shares of KRYS for $829,417 on Feb 28. The Chief Accounting Officer now owns 12,936 shares after completing the transaction at $165.88 per share. On Feb 26, another insider, ROMANO KATHRYN, who serves as the Chief Accounting Officer of the company, sold 8,087 shares for $136.91 each. As a result, the insider received 1,107,180 and left with 12,556 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KRYS now has a Market Capitalization of 4.83B and an Enterprise Value of 4.31B. As of this moment, Krystal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1921.71, and their Forward P/E ratio for the next fiscal year is 32.58. For the stock, the TTM Price-to-Sale (P/S) ratio is 95.33 while its Price-to-Book (P/B) ratio in mrq is 6.20. Its current Enterprise Value per Revenue stands at 84.97 whereas that against EBITDA is 240.60.
Stock Price History:
Over the past 52 weeks, KRYS has reached a high of $173.00, while it has fallen to a 52-week low of $70.51. The 50-Day Moving Average of the stock is 124.62, while the 200-Day Moving Average is calculated to be 118.57.
Shares Statistics:
For the past three months, KRYS has traded an average of 366.68K shares per day and 662.13k over the past ten days. A total of 28.24M shares are outstanding, with a floating share count of 23.57M. Insiders hold about 16.68% of the company’s shares, while institutions hold 84.39% stake in the company. Shares short for KRYS as of Feb 15, 2024 were 2.47M with a Short Ratio of 6.74, compared to 1.97M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.75% and a Short% of Float of 10.18%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.3 and a low estimate of -$0.29, while EPS last year was -$1.76. The consensus estimate for the next quarter is $0.19, with high estimates of $0.65 and low estimates of -$0.22.
Analysts are recommending an EPS of between $3.84 and -$1.19 for the fiscal current year, implying an average EPS of $1.27. EPS for the following year is $4.03, with 7 analysts recommending between $7.77 and $0.34.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for KRYS’s current fiscal year. The highest revenue estimate was $315.4M, while the lowest revenue estimate was $175.8M, resulting in an average revenue estimate of $239.74M. In the same quarter a year ago, actual revenue was $50.7M, up 372.90% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $416.31M in the next fiscal year. The high estimate is $575M and the low estimate is $251M. The average revenue growth estimate for next year is up 73.70% from the average revenue estimate for this year.
